相关实验视频
Updated: Mar 17, 2026

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
2.4K
家庭护理人员对在轻度认知障碍患者的家庭刺激的看法
Camille Bouhour1, Stefania Konstantopoulou1, Timothy Piton2
1Department of Clinical Neurosciences, University of Geneva, Geneva, Switzerland.
Journal of Alzheimer's disease : JAD
|March 16, 2026
概括
护理人员可以有效地为患有轻度认知障碍 (MCI) 的个人提供基于家庭的横交替电流刺激 (tACS),尽管存在一些日常生活干扰,但表现出高度的信心和接受.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 临床心理学 临床心理学
背景情况:
- 跨交替电流刺激 (tACS) 为神经和精神疾病提供了治疗潜力.
- 频繁的实验室访问限制了重复的tACS治疗的实际应用.
- 由护理人员管理的家庭tACS可以提高可访问性,特别是对于轻度认知障碍 (MCI) 患者.
研究的目的:
- 评估MCI患者的护理人员管理的家庭tACS的可行性和可接受性.
- 评估老年护理人员在tACS会议的远程临床监督期间的感知,信心和经验.
主要方法:
- 20名家庭护理人员 (平均年龄70岁) 接受了操作六电极tACS设备的培训.
- 护理人员在实时远程监督下对MCI患者进行了20次家庭tACS会议.
- 量化措施评估了护理人员的信心,负担和患者感知的益处.
主要成果:
- 护理人员表示对技术程序和令人满意的培训有很高的信心 (85-100%).
- 大多数护理人员 (85%) 感到舒服地独立管理tACS;90%会重复使用系统,尽管日常生活的干扰 (70%).
- 临床观察指出患者受益 (45%的护理人员,57%的患者),尽管生活质量和记忆效应是混合的.
结论:
- 护理人员管理的家庭tACS对于MCI患者的老年护理人员来说是可行的和可以接受的.
- 加强培训和持续的远程支持对于最小化护理人员负担和优化结果至关重要.
- 这些发现支持扩大护理人员提供的tACS协议,以改善患者的访问和遵守.
更多相关视频
06:13Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
Published on: March 1, 2024
1.9K
11:26Home-Based Transcranial Direct Current Stimulation Device Development: An Updated Protocol Used at Home in Healthy Subjects and Fibromyalgia Patients
Published on: July 14, 2018
18.0K
相关概念视频
Documentation in Long-Term and Home Healthcare Setting
1.6K
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
1.6K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K